Stockscreener 앱 받기
0.8307
3.62%
-0.0312
시장 영업 전:
.80
-0.0307
-3.70%
Assertio Holdings Inc 주식(ASRT)의 최신 뉴스
Geode Capital Management LLC Purchases 42,750 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Assertio Holdings Names New Chief Commercial Officer, Awards Major Stock Incentive Package - StockTitan
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. - AccessWire
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Up 14.1% in December - MarketBeat
Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment? - Simply Wall St
Assertio appoints new independent director to board By Investing.com - Investing.com South Africa
Assertio appoints new independent director to board - Investing.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times
Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan
Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada
Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat
Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com
Assertio reports positive Rolvedon trial results for breast cancer - Investing.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times
Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan
Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat
Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada
Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Acquired by Empowered Funds LLC - Defense World
Assertio Holdings Q3 2024 Earnings Preview - MSN
Assertio stock gains amid Q3 earnings, clash with activist investor - MSN
Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat
Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria
Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com
Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India
Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Quarterly 10-Q Report - Quartz
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Assertio Reports Third Quarter 2024 Financial Results - The Manila Times
Assertio: Q3 Earnings Snapshot - The Washington Post
Assertio Therapeutics’ Q3 2024 Earnings Overview - TipRanks
Assertio stock gains amid Q3 earnings, clash with activist investor (NASDAQ:ASRT) - Seeking Alpha
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Assertio Holdings, Inc. Announces Board Changes - Marketscreener.com
Assertio Holdings Faces SEC Whistleblower Complaint Over Alleged Clinical Data Fraud | ASRT Stock News - StockTitan
Assertio Provides Response to Letter from Short-seller - GlobeNewswire
Assertio Holdings CEO Fires Back at Short-Seller's 'Baseless' Rolvedon Claims | ASRT Stock News - StockTitan
Assertio Holdings (NASDAQ:ASRT investor five-year losses grow to 72% as the stock sheds US$17m this past week - Simply Wall St
Assertio faces fraud claims, investor goes short on stock By Investing.com - Investing.com India
Assertio Stock Alert: Major Investor Warns of Fraud Claims, Safety Issues in Spectrum Deal | ASRT Stock News - StockTitan
2.12%
0.89%
자본화:
|
볼륨(24시간):